The Future of adjuvant therapy for renal cell carcinoma

Sarah J. Welsh, Tobias Janowitz, Tim Eisen

Research output: Contribution to journalArticle

3 Citations (Scopus)


Twenty to thirty percent of patients with stage I-III renal cell carcinoma will relapse within 5 years of surgery. Recent advances in our understanding of the molecular pathogenesis of renal cell carcinoma have led to several large randomized clinical trials investigating the role of molecularly targeted agents in the adjuvant setting. However, there are higher than expected drop-out rates due to the intolerability of side effects compared with treatment given in the metastatic setting. Additionally, significant challenges remain in the area of clinical trial design and the need to assess multiple potential therapies in a time- and cost-efficient manner, and to identify which patients are likely to benefit from adjuvant therapy.
Original languageEnglish
Pages (from-to)451-462
Number of pages12
JournalClinical Practice
Issue number4
Publication statusPublished - 2012
Externally publishedYes

Fingerprint Dive into the research topics of 'The Future of adjuvant therapy for renal cell carcinoma'. Together they form a unique fingerprint.

Cite this